Dissertation > Excellent graduate degree dissertation topics show

Correlation of p16、p53、PCNA and VEGF Expression and Prognosis in Malignant Mesothelioma

Author: QinJun
Tutor: YuGuo
School: PLA Postgraduate Medical School
Course: Pathology and Pathophysiology
Keywords: Malignant mesothelioma Prognosis : p16 p53 PCNA VEGF
CLC: R730.7
Type: Master's thesis
Year: 2005
Downloads: 58
Quote: 0
Read: Download Dissertation

Abstract


Malignant mesothelioma is a primary malignant tumor derived from mesothelial cells, which have the characteristics of high-invasive, high mortality. The purpose of this study is to investigate the p16, p53, PCNA, VEGF and clinical biological behavior and prognosis of malignant mesothelioma organization to find sensitive and specific prognostic indicator for early diagnosis of malignant mesothelioma treatment and evaluation of patients provide clues to prognosis. MATERIALS AND METHODS: SP assay People's Liberation Army General Hospital from January 1984 to January 2004, 60 patients with malignant mesothelioma specimens. Analysis of p16, p53, PCNA, VEGF expression with histological type, clinical stage, and the lifetime of the relationship. The experimental results of Wilcoxon test was used for univariate analysis, the onset of the Kaplan-Meier product-limit method and life table survival analysis, fitting Cox regression model for multivariate statistical analysis of prognostic factors. Significance level of 0.05. Results: 1.p16 protein immune histochemical stain positive expression rate was 33.3% (20/60), negative expression rate was 66.7% (40/60); significant difference (p of p16 protein positive expression rates in different tissue types lt; 0.05); of p16 protein expression with malignant mesothelioma clinical stage increased reduced, p16 expression of positive and negative groups of patients, the average survival time (months), and the 95% confidence interval were 26.7 (24.1 , 29.3), 14.5 (12.6,16.4). patients with malignant mesothelioma survival was significantly greater than in patients with negative expression of p16 protein expression, significant difference (P lt; 0.05). 2.p53 immunohistochemical staining positive expression rate was 65.0% (39/60). p53 positive expression ratio in different clinical stages with a significant difference (P lt; 0.05). The expression of p53 positive and negative groups of patients, the average survival time (months) and 95% confidence interval were 17.2 (15.0,19.5) 21.0 (16.5,25.5). The positive expression of patient survival compared to patients with negative expression is decreasing, but they was no significant difference (P gt; 0.05). 3.PCNA immunohistochemical staining positive expression rate was 93.3% (56/60), the high expression rate was 61.7% (37/60). High expression group and the average survival time of patients with low expression group (months) and 95% confidence intervals were 16.4 (13.9,18.9) 22.0 (18.5,25.6). PCNA high expression of patient survival was significantly less than in patients with low expression, significant difference (P lt; 0.05). 4.VEGF immunohistochemical staining positive expression rate was 66.7% (40/60). VEGF expression of positive and negative groups of patients, the average survival time (months) and 95% confidence intervals were 16.7 (14.4,

Related Dissertations

  1. The Regulate and Controlof Slug on P53-MDM2 System,R730.2
  2. Research of Screening and Function of P53 Regulators in KZNF (AxZ Type、SABZ Type and ACxZ Type) Family,R730.2
  3. Effects of Angiopoietin-1 on Vascular Angiogenesis Regulator Factor in Human Umbilical Vein Endothelial Cells Cultured with High Glucose,R587.2
  4. Effects of the Applied External Weak Steady Direct Current Electrical Fields on Diastolic Function after Balloon Injury in the Rabbit Abdominal Aorta,R541.4
  5. Inhibition of Conventional Chemotherapy Combined with Metronomic Chemotherapy on Breast Cancer Xenografts in Nude Mice,R737.9
  6. The Affection and Correlation of VEGF、 SDF-1 to the Homing of Bone Marrow Hemopoietic Stem Cells in Myocardial Infraction Area,R542.22
  7. A Study of the Expressions of MT1FmRNA and VEGFmRNA in Acute Myelocytic Leukemia,R733.71
  8. The Expression of PI3K and P53 in Prostate Cancer and Its Clinical Significance,R737.25
  9. Protein Expressions of EGFR、K-ras、P53 and Ki-67 in Colorectal Cancer, Gastric Cancer and Esophageal Cancer,R735
  10. Influence of NF-κB Inhibitor (PDTC) on Protein Expression of ASPP1 and ASPP2 of Non-small Cell Lung Cancer,R734.2
  11. Research of Expression and Clinical Significance of p53、PCNA and PTEN in Gastric Cancer,R735.2
  12. Expression of NRP-2 and VEGF in Colorectal Adenocarcinoma and Colorectal Adenoma Tissues,R735.34
  13. Establishment and Study of the Cultured Model of Microencapsulated Human Gastric Carcinoma Cells,R735.2
  14. The Molecular Biology of Rh-endostatin Plus Chemotherapy as Adjuvant Treatment for Non-small Lung Cancer,R734.2
  15. Clinical Study on the Expression of VEGF in Liver Metastases of Colorectal Cancer and Its Effect on Prognosis,R735.3
  16. The Analysis of the Growth Factor Related with the Secondary Glaucoma in the Anterior Champer of Silicone Oil-filled Eyes,R779.6
  17. Ginsenoside Rg3 combined IRESSA on human A431 cell growth,R285.5
  18. OVCA1 and P53 in ovarian serous tumor tissue,R737.31
  19. Bax and VEGF in endometrial carcinoma and its significance,R737.33
  20. Experimental Studies on Therapy of Lung Cancer by VEGF-C siRNA Mediated by Liposomes,R734.2
  21. Expression of hPOT1、p53 and Their Relationship with HP Infection in Gastric Carcinoma,R735.2

CLC: > Medicine, health > Oncology > General issues > Prognosis
© 2012 www.DissertationTopic.Net  Mobile